ERBB2 and breast carcinoma: Shimizu and colleagues[54], in a study with breast cancer cell line, suggested that the α6β1 integrin inhibits HER-2 signals by proteolytic cleavage of the cytoplasmic domain of HER-2 and this could also contribute to the regulation of tumor growth.